Candel Therapeutics, Inc. Common Stock (CADL) is a publicly traded Healthcare sector company. As of July 13, 2026, CADL trades at $9.76 with a market cap of $695.33M and a P/E ratio of -13.15. CADL moved +2.74% today. Year to date, CADL is +66.20%; over the trailing twelve months it is +54.31%. Its 52-week range spans $3.83 to $14.60. Analyst consensus is strong buy with an average price target of $21.50. Rallies surfaces CADL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest CADL news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $9.76 |
| Market Cap | $695.33M |
| P/E Ratio | -13.15 |
| EPS | $-0.72 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.60 |
| 52-Week Low | $3.83 |
| Volume | 654.76K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-38.18M |
| Gross Margin | 0.00% |
6 analysts cover CADL: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.50.